Accordingly, combined pharmacological inhibition of MEK using selumetinib and PI3K using AZD8186 inhibited tumour growth and increased survival in mice [43], pointing towards a potential novel targeted strategy for sarcomatoid mesothelioma. The gene discussed is MAP2K7; the disease is neoplasm.